Researchers validate first-ever AI biomarker for ADT benefit

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

Related Keywords

Case Western Reserve University , Ohio , United States , Canada , Americans , American , Lee Seidman , Daniel Spratt , Theodoros Teknos , Danielle Ellis , Vincentk Smith , Gary Schwartz , Danieli Simon , Cancer Center , Department Of Radiation Oncology , Case Comprehensive Cancer Center , University Hospitals Uh Seidman Cancer Center , Academic External Affairs , University Hospitals , Case Comprehensive Center , Uh Seidman Cancer Center , Seidman Cancer , Northeast Ohio , Radiation Oncology , Case Western Reserve , Case Comprehensive Cancer , African American , University Hospitals President , External Affairs , Chief Scientific Officer , Patti Novak Distinguished Chair , Healthcare Leadership , Scientific Director , Lee Seidman Chair , Cancer Innovation , Seidman Cancer Center , African Americans , Cancer , Androgen , Androgen Deprivation Therapy , Artificial Intelligence , Biomarker , Children , Hospital , Medicine , Ncology , Prostate , Prostate Cancer , Radiotherapy , Research , Technology ,